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Abstract
Background: Cervical Cancer is still a major public health challenge in low and middle-income countries. HPV
testing has been an innovative approach, which was introduced in Argentina for women aged 30+ through the
Jujuy Demonstration Project (JDP) carried out between 2012 and 2014. After a positive HPV-test, cytology is used as
triage method. Under this protocol, the group of women with HPV+ and normal cytology are recommended to
repeat the test within 12–18 months. Studies have shown that this group has increased risk of CIN2+, however,
assuring high levels of repeating test among these women is difficult to achieve. We analyze those factors
associated with lower re-test attendance among HPV+/ cytology negative women at a programmatic level in low-
middle income settings.
Methods: We used data of women aged 30+ HPV-tested in the JDP and followed until 2018 (n = 49,565). We
performed a set of different adjusted logistic regression models.
Primary outcomes were re-test attendance and re-test attendance within recommended timeframe. We assessed as
covariates age, health insurance status, year of HPV-testing, Pap testing in the past 3 years, HPV-testing modality
(clinician-collected (CC) tests/self-collected (SC) tests), and span between HPV-test collection and report of results.
Results: Forty nine thousand five hundred sixty five women were HPV-tested and 6742 had a positive HPV-test.
Among HPV+ women, a total of 4522 were HPV+/Cytology negative (67.1%). In total, 3172 HPV+/Cytology negative
women (70.1%) had a record of a second HPV test as of March 2018. Only 1196 women (26%) completed the
second test within the timeframe. Women with no record of a previous Pap (OR: 0.46, 95% CI: 0.4–0.53, p < 0.001),
aged 64+ (OR: 0.46, 95% CI: 0.31-0.68, p < 0.001) were less likely to be retested; while women with clinician-
collected samples had higher odds of being re-tested (OR: 1.42, 95% CI: 1.06–1.91, p < 0.001).
Conclusions: Low re-test rates were found in HPV +/ normal cytology women. Tailored interventions are needed
to increase the effectiveness of the screening in this group, especially for those women with characteristics
associated to lower attendance.
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Background
Cervical cancer is still a major public health challenge in
low and middle-income countries. Unsuccessful screen-
ing strategies have been pointed out as one of the major
barriers to reduce the morbidity and mortality [1]. Cy-
tology screening presented a particular set of problems,
as it required frequent examinations and rigorous quality
controls to compensate for its low negative predictive
value, low-moderate sensitivity and highly variability
depending on the operator [2]. Introduction of HPV
testing is an innovative approach in cervical cancer
screening programs, which can help to overcome certain
limitations of cytology-based schemes. Automated HPV
test processing and interpretation reduces the need for
cytotechnicians and quality controls. Also, its high sensi-
tivity and negative predictive value allows extension of
the screening interval [3, 4]. Furthermore, after the
introduction of HPV vaccination, HPV test is recom-
mended as the test for primary screening [2, 5].
Nonetheless, screening strategies based on HPV
testing as primary screening have opened new chal-
lenges; one is the fact that HPV-testing identifies
women positive for HPV but does not inform which
of these women have pre-neoplastic disease. In order
to identify those women with lesions that need to be
referred for further diagnosis, triage methods are
used. Many countries use cytology for triage, includ-
ing Argentina, and it is one of the recommended
methods indicated by WHO guidelines [5]. Cytology
as triage after HPV-test is more sensitive than cy-
tology read without knowledge of the HPV status [6].
In this protocol, women who are HPV+ with abnor-
mal cytology are referred for further diagnosis and
treatment as needed, and HPV-negative women are
generally recommended re-screening at 3–5 years. In
Argentina, national guidelines decided by agreement
with scientific societies that rescreening is recom-
mended at 5 years [7]. For the sub-group of women
who are HPV+/ cytology negative the recommenda-
tion is to repeat the HPV-test within 12 to 18 months
[8]. Many of these infections are transient and will re-
gress spontaneously, hence referring these women for
colposcopy would imply overburdening diagnostic ser-
vices with women whose risk of CIN2+ appear to be
low [7] and it might also cause unnecessary psycho-
logical distress.
Assuring high levels of re-test among these women
is particularly important, as studies have shown that
they are at increased risk of CIN2+, even when the
repeat HPV test is negative [8, 9]. Re-testing them at
12–18 months allows identifying persistent infections.
In addition, there is also a problem linked to the
moderate cytology sensitivity, which might result in
CIN2+ lesions being missed by triage; sensitivity of
the triage PAP is increased when women are
retested.
However, despite the importance of following-up this
group, evidence indicates that assuring high levels of
re-test among these women is difficult to achieve [10],
especially in settings where no call/recall systems are in
place [11].
Evidence from cytology-based programs has shown
that in general, completion of follow-up steps and adher-
ence to recommended timeframes is especially difficult
to achieve for women with low socio-economic level, as
well as for those who face geographic, and health system
barriers to health care [12–16]. These factors that affect
follow-up in cytology-based programs might also be af-
fecting re-test of HPV+/cytology negative women, how-
ever, there might also be factors derived from the
HPV-testing context.
As today, there is no study assessing factors that
might be associated with lower rate of re-test among
HPV+/ cytology negative women in programmatic
context in low-middle income populations. In
Argentina HPV-testing was first introduced through
the Jujuy Demonstration Project (JDP), during 2012–
2014 [14] . We analyzed data from the JDP to iden-
tify those factors that might be associated with lack
of re-testing among HPV+/cytology negative women.
Methods
Materials
We analyzed data collected for the JDP, carried out be-
tween 2012 and 2014 [14]. The JDP has been extensively
described elsewhere [14, 15], but succinctly it introduced
HPV-testing as primary screening for women aged 30
years and older attending the public health system. The
programmatic target population was 30–64 years old,
however screening was also provided to women aged 65
and over if requested. HPV samples were collected by
health professionals at health centers, and since 2014
HPV self-collection was introduced as a programmatic
strategy to increase screening coverage [15, 16]. Based
on results of the JDP, HPV-testing was incorporated as
primary screening at country level. The type of screening
was mainly opportunistic, except for those women using
self-collected method, who were reached by health
workers during home visits using a nominalized list.
Women were informed of their results at health care
centers. Appointments for repeating the test were ar-
ranged at this visit in case of HPV+/cytology negative
results.
Data of the JDP was registered in the National Screen-
ing Information System, (SITAM, by its initials in Span-
ish) implemented by the National Cervical Cancer
Prevention Program (NCCPP). SITAM is a unified data-
base that collects data about screening, diagnosis and
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treatment of all women attending the public health sys-
tem. Those that were initially screened by the public sec-
tor but continued their follow-up in private services
were recorded in SITAM only upon confirmation by the
provincial prevention program; otherwise they were con-
sidered as loss to follow-up. For this analysis, we in-
cluded women aged 30 years and older HPV-tested
between 2012 and 2014 for the first screening test and
data until 2018 for their re-test. We do not consider sec-
ond tests that were done after a five-year period. De-
tailed description of how data is collected by the NCCPP
is described elsewhere [14, 16]. The data are accessed by
authorized healthcare workers and researchers. A
non-disclosure agreement of the personal data is signed
before a user and password is provided to access to the
databases.
Independent variables and outcome
Independent variables considered for this study were
age, health insurance status, year of HPV-testing, record
of previous Pap, HPV-testing modality (clinician-col-
lected (CC) tests/self-collected (SC) tests), and span be-
tween HPV-test collection and report of results. This
last variable is included as a proxy measuring the labora-
tories’ time efficiency processing the samples.
Primary outcomes were re-test attendance, and re-test
attendance within recommended timeframe, both re-
corded as dichotomous variables. Re-test was considered
within the recommended time frame when was per-
formed between month 12 and 18 after primary screen-
ing [17]. Women who returned up to 30 days off the
range were also included.
Statistical analysis
We performed a set of descriptive statistics and different
logistic regression models.
First, a multivariable regression was used to examine
the association with re-test attendance of the following
variables: age, health insurance status, year of
HPV-testing, record of a previous Pap test, HPV-testing
modality, and span in days between HPV-test collection
and when result report was available in the system. We
report odds ratios with 95% confidence intervals and
p-values.
Secondly, we analyzed factors associated with re-test
attendance within the recommended timeframe as out-
come. Last, we performed a logistic regression including
only women with re-screening test to assess the associ-
ation of the covariates and the outcome within this
group. This model worked as a sensitivity analysis model
that helped to evaluate the association of the covariates
and the outcome in this subset of women.
In order to explore possible interactions between the
covariates, we tested different regressions including
interaction terms for each pair of variables. Furthermore,
we ran a model stratifying the data by year to confirm
the associations for each year data. R Statistical software
and R-Studio were used to perform the analysis.
Results
For the period 2012–2014, 49,565 women were tested
using HPV-test as primary screening test. Socio-demo-
graphic characteristics of these women are presented in
Table 1. Of the total screened women, 6742 had a posi-
tive HPV-test, of which 4522 were HPV+/Cytology nega-
tive (67.1%). In total, 3172 HPV+/Cytology negative
women (70.1%) have a record of a second HPV test as of
March 2018. When the recommended timeframe is
taken into consideration, 1196 women (26%) attended
for re-screening at months 12–18 (Fig. 1). The median
time for re-screening was 656.5 days, being the first
quartile 411.2 and the third quartile 1015 days. The re-
sults for the second HPV test were positive for 1412
women (44.5%) and negative for 1759 (55.5%).
Results of the multivariate regression are shown in
Table 2. The odds of being re-screened was 0.46 times
among women with no record of a previous Pap test
when compared to those who do had it (OR:0.46, 95%
CI: 0.4–0.53, p < 0.001). Moreover, those women aged 64
+ were also less likely to be re-screened, having 0.46
Table 1 Socio-demographic characteristics of HPV+/Cytology-
women. Jujuy
With HPV re-test Without HPV re-test
n % n %
Age
Mean (Years) 40.16 SD (9.61) 41.61 SD (10.99)
30–34 1193 36.6 461 34.15
35–44 1115 34.8 457 33.85
45–54 512 16.4 231 17.11
55–64 290 9.4 136 10.07
65+ 59 2.7 64 4.74
Previous PAP
No 1657 52.24 971 71.93
Yes 1515 47.76 379 28.07
Health Insurance
Public 2143 67.56 869 64.37
Private 1026 32.35 478 35.41
HPV-testing modality
Self-Collected 125 3.94 133 9.85
Clinician-Collected 3047 96.06 1217 90.15
Span to re-test
Within range 1196 37.62
Outside range 1983 62.38
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times the odds of being re-screened when compared to
those aged 30–34 (95% CI: 0.31-0.68, p < 0.001). Women
with CC tests had 1.42 times the odds of being
rescreened compared to those with SC HPV-tests (95%
CI: 1.06–1.91, p < 0.001). Women HPV-tested during
2013 and 2014 were less likely to be re-screened (OR:
0.65, 0.48; 95% CI: 0.56-0.76, 0.4–0.58, respectively with
p < 0.001). Stratifying by year, results are consistent, be-
ing age, record of a previous Pap test, and HPV-test col-
lection modality significant predictors. No significant
interaction was found in the model testing all the covari-
ates pairs.
When the outcome considered for the model was
re-screening within the recommended time frame,
being CC HPV-tested increased 2.10 times the odds
of re-screening within 12–18 months (95%, CI: 1.36–
3.32, p < 0.001), while women with no record of a
previous Pap test were less likely to be-rescreened
within 12–18 months (OR: 0.82, 95%, CI:0.71–0.95, p
= 0.02).
Among the subset of re-screened women, the odds of
re-screening within the recommended timeframe were
reduced for those without record of a previous Pap test
(OR: 0.84, 95% CI: 0.72–0.96, p = 0.016). On the con-
trary, women who had CC HPV-testing were more likely
to be re-screened within the recommended timeframe.
(OR: 2.82, 95% CI: 1.70–4.82, p < 0.001). The other co-
variates showed no statistically significant results.
Fig. 1 Percentage of women with a HPV re-test over time
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Discussion
This is the first study analyzing factors associated with
attendance to re-testing by HPV+/cytology negative
women using a large database of a low-middle income
population where HPV testing is the primary screening
method.
Screened women with an HPV +/ cytology negative re-
sult is a group that did not exist in cytology-based pro-
grams. In settings using HPV-testing and cytology for
triage most HPV+ women will have normal triage cy-
tology as result and will need re-screening at 12–18
months. Analyzing this subset of women in a separate
way is important, since their overall risk of developing
cervical cancer is increased [8]. They might also be fa-
cing specific barriers to follow-up, if for example they do
not understand the meaning of the test/triage results.
Thus HPV+/cytology negative women might behave dif-
ferently regarding healthcare decisions [18, 19].
Our study found that HPV+/ cytology negative women
with no previous record of a Pap test, aged 65+ and with
SC tests are less likely to be re-tested. If the 12–18
months period for re-test is considered, women with
SC-tests and with no Pap smears in the past have a de-
creased probability of being retested.
In our study, the overall rate of re-screening was
70.1%, close to what has been found by the POBASCAM
study in Amsterdam, where the re-testing rate was 77%,
and by Rijkaart et al. who reported a rescreening rate of
60% [10]. Pasquale et al. [20] and Passamonti et al. [21]
reported -in well-organized programs in Italy- a higher
percentage of HPV+/cytology negative women being
retested (84%). However, in our study, if the 12–18
month recommendation is considered, the re-screening
rate drops significantly, as only 26% of re-screened
women did the test within this timeframe. The de-
creased percentage of women attending to re-testing
within recommended timeframes has been reported in
high income-countries as well. A study in Denmark
showed that 58% of women being retested attended
within 18months [22]. Low re-testing rates within rec-
ommended timeframes has also been a problem in
cytology-based programs. In the US, about 20% of
Table 2 Multivariate logistic regression. Variables associated with having an HPV re-test. Jujuy Province, Argentina
OR (95% CI) OR (95% CI)
With HPV re-test regardless date With HPV re-test between12 to 18 months
Age (years)
30–34 ref. ref.
35–44 0.98 (0.84, 1.15) 0.91 (0.77, 1.08)
45–54 0.87 (0.72, 1.07) 1.01 (0.82, 1.25)
55–64 0.83 (0.65, 1.05) 0.95 (0.72, 1.23)
65+ 0.46*** (0.31, 0.68) 1.36 (0.79, 2.32)
First HPV-test year
2012 ref. ref.
2013 0.65*** (0.56, 0.76) 0.97 (0.83, 1.14)
2014 0.48*** (0.40, 0.58) 1.13 (0.92, 1.40)
Health insurance
Private ref. ref.
Public 1.01 (0.88, 1.17) 1.10 (0.94, 1.29)
Record of previous PAP
Yes ref. ref.
No 0.46*** (0.40, 0.53) 0.82 *(0.71, 0.95)
Time from sample taking to report emission
Less than a month ref. ref.
More than a month 0.84 (0.62, 1.14) 1.10 (0.78, 1.53)
HPV-testing modality
Self-collected ref. ref.
Clinician-collected 1.42** (1.06, 1.91) 2.10*** (1.36, 3.32)
Constant 4.09*** (2.82, 5.95) 0.31*** (0.18, 0.50)
OR odds ratio, CI confidence interval
p-values: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1
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women eligible for cervical cancer screening have not
been reached by screening programs within the time-
frame recommended [23, 24]. These studies show that
low-income groups, recent immigrants, and ethnic mi-
norities have the lowest follow-up rates. [25] Other stud-
ies carried out in other high income countries have
found similar disparities [26].
Factors associated to the loss to follow-up in cervical
cancer prevention have been generally discussed, how-
ever, there is almost no information published about
specific factors associated to loss to follow-up in the
group of HPV+/cytology negative women [27]. The vari-
ables our study found associated to loss to follow-up
were mainly related to the prior screening history, age
and type of screening modality. These factors has been
described as proxies for reduced access to health ser-
vices [1, 15].
Studies that analyzed why screened women with
positive results failed to complete follow-up and treat-
ment in America Latina found that in most cases the
reasons were related to a deficient health services
organization and subjective factors [18, 28–31]. For
example, in a study carried out in Jujuy before
HPV-testing was introduced, delays in result delivery
or not receiving results at all was the most commonly
reported problem by women, followed by problems
with appointment dates, and long waiting times [28].
In addition, in that study, 30% of the women reported
subjective reasons, including fear, unwillingness to
continue with the treatment, lack of proper informa-
tion about the disease [28].
Luque et al. [32] found that age, marital status, and
number of previous medical office visits were factors
associated with adherence to the recommendations in
the US. Rendle et al. [19] found that among HPV
negative women from northern California HPV
screening program, African American, Hispanic and,
American Indian were more likely to be rescreened
passed the interval recommended. Although these
studies were performed in a high-income country, age
and number of previous medical office visits are simi-
lar to those we found in our study.
In our study, women aged 65+ were less likely to be
re-screened. Beavis (2017) and Li (2017) found that
women in this age group have a higher rate of HPV per-
sistent infection and a higher incidence of cervical can-
cer [33, 34]. Furthermore, Skaznik-Wikiel et al. (2012)
concludes that the incidence of cervical cancer does not
decrease significantly in older women and that women
aged 70+ are frequently diagnosed when the disease has
reached advanced stages, reducing treatment options
[35]. This underscore the importance for prevention
programs to enhance follow-up strategies focused on
this age group.
Our study also found significant reduced odds of at-
tending to rescreening among those women with no pre-
vious record of a Pap. In line with what other authors
discussed, this factor seems to be linked to persistent
socio-economic and geographic barriers to access health
services, as well as the inadequacy of the health system
to provide required services, indicating not only a barrier
in the past, but a lasting obstacle to for appropriate
follow-up [14, 31].
Moreover, women with CC HPV-Tests were at in-
creased odds of re-screening. Women offered SC tests in
the JDP were socially vulnerable women, with reduced
access to screening [16]. Arrossi et al. (2016) described
that one main reason why women choose HPV SC-tests
is because it simplifies their health care process and re-
duce barriers such as responsibility for domestic work,
work and family organization issues, and troubles navi-
gating health care services’ organization [36]. Therefore,
while self-collection highly increased their access to
screening [15], social and health system barriers might
still be operating in the continuation of the follow-up
process. In addition, women screened at health centers
might also have increased access to information about
what are the implications of an HPV +/ Cytology – re-
sult from health workers and professionals.
There are different strategies described for decreas-
ing the number of lost to follow-up in cervical cancer
screening. Referral to colposcopy of these women im-
plies a significant burden for the health system that
will not be translated in better screening outcomes
[17]. Setting up specific strategies to overcome bar-
riers in the access to health services, such as improv-
ing the availability of appointments, as well as the
implementation of effective technical and logistical
changes on how to deliver the results has been
pointed out as solutions to improve the adherence
rates [37]. The implementation of mHealth interven-
tions in this settings are currently being evaluated as
an strategy to reduce lost to follow-up [38].
Notwithstanding the useful information provided by
this study for future research on HPV+/Cytology nega-
tive women, and the contribution for further program-
matic evaluations, a number of limitations exist. First,
the population analyzed is that targeted and reached by
the NCCPP, which might not be representative of the
whole population. Also, the variables observed were
those that the program collects as routine, other signifi-
cant variables were not possible to include in the ana-
lysis. Further studies are needed to scale up these
conclusions. Second, the nature of this study is observa-
tional, and it is not conclusive evidence of causal rela-
tionship between the variables analyzed and the
outcome. Moreover, while in randomized study designs
it is expected that unobserved confounders are randomly
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distributed among the groups without affecting the asso-
ciation between exposure and outcome, in this study -an
observational study- unobserved confounder might be
biasing the results.
Furthermore, the lost to follow-up is also a limitation
for this study, since women that opt to continue their
follow-up using private health providers are not neces-
sarily included in SITAM.
Conclusion
The transition to HPV test-based screening programs
has defined a new group of women, those with an HPV
+/normal cytology result. Low re-testing and low adher-
ence to protocol recommendations have been found in
this population. Our study found three factors associated
to low attendance to re-screening: women without rec-
ord of a previous Pap test, being aged 64+ and being
screened with SC-tests. Further studies are needed to
properly assess the risk of this group of women, and spe-
cific interventions might be needed to increase the
effectiveness of the screening programs among HPV
+/Cytology negative women. Particularly, among the
groups that this study found associated to higher lost to
follow-up, setting tailored measures, such as the reduc-
tion of barriers in the access and the implementation of
logistics changes on how to deliver the results should be
considered for future interventions.
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